Cancer Immunotherapy Denied by Insurance? How to Appeal

Cancer immunotherapy — including checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo), CAR-T cell therapies, tumor-infiltrating lymphocyte (TIL) therapy, and cancer vaccines — represents some of the most effective treatments available for certain cancers. With costs reaching $500,000 or more per course, denials are common and devastating. The good news is that immunotherapy denials are among the most legally vulnerable insurance decisions, and appeals grounded in FDA approval evidence and NCCN guidelines succeed at a meaningful rate.

Why Insurers Deny Cancer Immunotherapy

Immunotherapy denials follow recognizable patterns. Identifying which applies to your case determines the evidence your appeal must include.

• "Experimental or investigational": Despite full FDA approval, checkpoint inhibitors and CAR-T therapies are sometimes denied as experimental — particularly for recently approved indications or when the patient's tumor subtype falls near the edge of the labeled indication. For FDA-approved therapies used within approved indications, this classification is factually wrong.
• "PD-L1 threshold not met": Many pembrolizumab approvals require specific PD-L1 expression levels (CPS or TPS). Incomplete biomarker documentation or scores near a threshold can result in denial even when treatment is clinically appropriate.
• "Wrong line of therapy": Insurers may deny because they claim the patient has not met the required number of prior treatment lines, or that immunotherapy is being sought in an earlier or later line than they believe is covered.
• "Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained or expired": Immunotherapy regimens require extensive prior authorization. Expired or missing PA results in denial even for clearly covered therapies.
• "Not medically necessary": The insurer's reviewer determines the patient's performance status, biomarker profile, or disease characteristics do not meet internal criteria that may be more restrictive than FDA labeling and NCCN guidelines.
• "Out-of-network facility": Immunotherapy at a specialized cancer center outside the plan network.

How to Appeal a Cancer Immunotherapy Denial

Step 1: Document All Biomarker Testing Completely

The most common reason otherwise valid immunotherapy claims are denied is missing biomarker documentation. Ensure your record includes: PD-L1 IHC result (CPS or TPS) using the validated companion assay for your specific drug and indication; MSI-H/dMMR status (which provides tumor-agnostic Keytruda eligibility across all solid tumors under FDA approvals); TMB-H status (≥10 mut/Mb, which provides tumor-agnostic Keytruda eligibility after prior treatment); and cancer-specific molecular markers such as BRAF V600E, EGFR, ALK, ROS1, KRAS, HER2, NTRK, RET, and MET where applicable.

Step 2: Verify FDA Approval for Your Exact Indication

Immunotherapy approvals are highly indication-specific — tumor type, biomarker requirement, prior treatment lines, combination versus monotherapy all matter. Cross-reference the FDA label and NCCN guidelines for your cancer type to confirm you are within the approved indication. An insurer denying an FDA-approved therapy for an FDA-approved indication has an extremely difficult legal and clinical position to defend.

Step 3: Identify the NCCN Category Evidence Level

Find the specific NCCN Category 1 recommendation for your treatment in the guideline for your cancer type. Category 1 (high-level evidence plus uniform NCCN consensus) is the strongest possible recommendation in oncology. Many state laws require insurers to cover NCCN-recommended treatments — check your state's specific cancer treatment mandate. ACA-compliant plans must cover medically necessary cancer care as an essential health benefit under 42 U.S.C. § 18022.

Step 4: Request Expedited Appeal Immediately

Cancer treatment denials are medically urgent. Under 29 CFR § 2560.503-1(f) for ERISA plans and ACA regulations for fully insured plans, you are entitled to an expedited internal appeal decided within 72 hours when delay would jeopardize your health. For CAR-T therapy specifically, the 3–6 week manufacturing lead time makes every day of delay clinically significant — state this explicitly in your expedited appeal request.

Step 5: Submit a Comprehensive Internal Appeal

Your appeal letter must include: the specific denial reason rebutted point by point; FDA approval documentation for the specific immunotherapy and your indication; the NCCN guideline excerpt showing Category evidence level; complete biomarker testing results; prior treatment history with dates, regimens, responses, and reasons for discontinuation; and your oncologist's letter of medical necessity citing NCCN guidelines. For TIL therapy (Amtagvi/lifileucel), note the FDA approval date of February 2024 for advanced melanoma and cite NCCN recognition even if the plan has not yet established PA criteria.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review and State Regulators

If the internal appeal fails, file for external review requesting an oncology specialist reviewer. Also file a complaint with your state's Department of Insurance. More than 40 states have specific cancer treatment mandates that may apply to your situation. For ERISA employer-sponsored plans, file a complaint with the Department of Labor's Employee Benefits Security Administration.

What to Include in Your Appeal

• Denial letter with specific reason codes and policy citation
• FDA approval documentation for the specific immunotherapy and your exact indication
• NCCN guideline excerpt showing Category evidence level for your treatment
• Complete biomarker testing results (PD-L1 IHC, MSI/MMR, TMB, and cancer-specific markers)
• Complete prior treatment history with dates, regimens, and documented progression
• Oncologist's detailed letter of medical necessity citing NCCN guidelines and biomarker profile
• Multidisciplinary tumor board recommendation if available — NCI-designated cancer center tumor board recommendations carry particular weight
• ECOG or Karnofsky performance status documentation
• All prior authorization correspondence and insurer communications

Fight Back With ClaimBack

Immunotherapy denials require precise documentation of biomarkers, FDA approval details, NCCN Category evidence citations, and prior therapy line records. A weak appeal letter is insufficient for the clinical and legal complexity of these cases. ClaimBack generates a professional cancer immunotherapy appeal letter in 3 minutes — grounded in the specific clinical and legal arguments that matter for your case.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal